Rottendorf Pharmaceuticals continues growth with multiple new deals with top 5 pharma companies for solid dose development and manufacturing

Rottendorf Pharmaceuticals, a top 20 contract development and manufacturing organization (CDMO) currently producing 600 products for more than 200 clients worldwide, announced it signed in the last quarter three formulation development projects and two commercial transfer projects with multiple Top 5 Pharmaceutical and Biopharmaceutical  companies. The five new projects capped a strong year of growth for the U.S.-based subsidiary of Rottendorf Pharma GmbH, which has more than doubled its share of corporate revenue since 2011.

“The new projects signed in the last quarter reflect the industry’s positive response to our business model and our commitment to Total Process Ownership™ (TPO),” said Rottendorf Pharmaceuticals CEO Gordon Haines. “TPO relies on open communication and exchange of ideas with our pharma partners and draws on 85 years of formulation development and manufacturing experience to recommend process optimizations to ultimately produce a better end product.” Under Total Process Ownership, Rottendorf assumes a high degree of process responsibility and ownership. Benefits to clients of TPO include reduced management oversight; lower costs due to reduced complexity; supply chain improvements; and products of the highest quality at the lowest total cost.

Haines noted that a significant number of new clients come to the company as a result of word-of-mouth referrals from satisfied clients who have benefited from the proactive approach Rottendorf takes to process improvement. Clients also appreciate the CDMO’s unique corporate structure. “We are owned by a charitable foundation, which allows us to focus more on long-term success of our business and the goals of our customers, rather than needing to satisfy shareholders on a quarter-by-quarter basis,” Haines added.

Five separate 2015 CMO Leadership Awards recently presented to Rottendorf by Life Science Connect reflect this laser-sharp focus on long-term customer success. The awards reflect survey results of more than 65,000 questionnaires sent to a broad swath of the industry including both pharma and biotech companies. Rottendorf won two awards for Quality (from both big pharma and emerging biotech firms); Productivity (from mid-sized and specialty pharma); Innovation (from emerging pharma); and Regulatory (from emerging biotech firms).

“These awards show that our customers appreciate the proactive approach we take to working with them and serve as further proof that our unique approach resonates with the market,” concluded Haines.

To learn more about Rottendorf Pharmaceuticals’ distinctive capabilities in the formulation, production and packaging of solid dosage forms, schedule a visit with us at DCAT Week ‘15, March 16 to 19 in New York City. For more information about DCAT Week ’15, presented by the Drug, Chemical & Associated Technologies Association, visit http://www.dcat.org/Pages/week_DCATWeek.aspx.